The prostate represents an excellent system for studying the function and molecular regulation of adult epithelial stem cells in the context of both tissue regeneration and cancer. The prostate epithelium is comprised of three differentiated cell types: luminal secretory cells, basal cells, and neuroendocrine cells ([Fig. 1a](#F1){ref-type="fig"})[@R1]. Androgen-deprivation leads to rapid apoptosis of approximately 90% of luminal cells and a small percentage of basal cells, although a stable cell number is maintained in the regressed state[@R2],[@R3]. Following re-administration of androgens, the prostate epithelium regenerates over approximately two weeks[@R2]--[@R4], and is capable of more than 15 rounds of serial regression/regeneration[@R5],[@R6], implying that the prostate epithelium contains a long-term population of castration-resistant stem cells.

Substantial evidence supports the existence of a basal stem cell population in the prostate[@R7], consistent with analyses of progenitor cells in other epithelial tissues[@R8]. In particular, subpopulations of basal cells isolated using cell-surface markers display bipotentiality and self-renewal in explant culture and tissue grafts[@R9]--[@R13]. Furthermore, single Lin^−^Sca-1^+^CD133^+^CD44^+^CD117^+^ cells, which are predominantly basal in the mouse and exclusively basal in the human, can reconstitute prostatic ducts in renal grafts[@R14]. However, explants from *p63* null mice can form prostate tissue and undergo multiple rounds of serial regression/regeneration in the absence of basal cells[@R15], suggesting the existence of a distinct luminal stem cell population. To date, however, luminal stem cells have not been identified in the prostate or other stratified epithelial tissues.

Although basal stem/progenitor cells have been proposed to represent a cell type of origin[@R7],[@R16],[@R17], human prostate cancer has a strikingly luminal phenotype. Notably, the absence of basal cells is a diagnostic feature for prostate adenocarcinoma[@R18],[@R19], suggesting either that prostate cancer arises from a luminal cell, or that oncogenic transformation of a basal progenitor results in rapid differentiation of luminal progeny. Here we show that expression of the *Nkx3.1* homeobox gene in the androgen-deprived prostate epithelium marks a rare luminal cell population that displays stem/progenitor properties during prostate regeneration. Our findings also indicate the relevance of this luminal stem cell population as a cell type of origin for prostate cancer.

Detection of CARNs in the prostate {#S1}
==================================

The *Nkx3.1* homeobox gene regulates prostate epithelial differentiation, and is frequently inactivated at early stages of prostate tumorigenesis[@R20]. Notably, *Nkx3.1* homozygous mutant mice develop prostatic intraepithelial neoplasia (PIN), a precursor of prostate cancer, by one year of age[@R21]--[@R23]. In the intact adult mouse prostate, all luminal cells express *Nkx3.1*, while 9.5% of p63^+^ basal cells (n=4291) also express *Nkx3.1* ([Fig. 1b](#F1){ref-type="fig"}; [Supp. Fig. 1a](#SD1){ref-type="supplementary-material"})[@R24]. Previous studies have shown that *Nkx3.1* expression in prostate epithelial cells is reduced or abolished in the absence of androgens *in vivo*, and is consequently androgen-dependent[@R25],[@R26]. Thus, Nkx3.1 expression is rapidly lost following castration, while Nkx3.1 expression is quickly restored after androgen re-administration to induce prostate regeneration ([Fig. 1c,d](#F1){ref-type="fig"}; [Supp. Fig. 1b](#SD1){ref-type="supplementary-material"}).

However, Nkx3.1 expression is not completely absent in the regressed prostate, but is instead retained in a rare population of epithelial cells ([Fig. 1c,e](#F1){ref-type="fig"}). These [**CA**]{.ul}stration-[**R**]{.ul}esistant [**N**]{.ul}kx3.1-expressing cells (CARNs) comprise 0.7% of total epithelial cells (n=38,329) in the anterior prostate of androgen-deprived males, or approximately 460 CARNs per mouse ([Supp. Table 1](#SD1){ref-type="supplementary-material"}). In addition, CARNs are frequently clustered ([Fig. 1e](#F1){ref-type="fig"}), and can be detected in the ventral and dorsal prostate, as well as after a second round of regression ([Supp. Fig. 1c--f](#SD1){ref-type="supplementary-material"}).

Importantly, all CARNs in the regressed prostate are strictly luminal, since they never express the basal cell marker p63 (n=0/379) or the neuroendocrine marker synaptophysin (n=0/610) ([Fig. 1f](#F1){ref-type="fig"}; [Supp. Table 1](#SD1){ref-type="supplementary-material"}). Instead, CARNs express the luminal markers cytokeratin 18 (CK18) (n=828/837) and androgen receptor (AR) (n=46/46) and are growth-quiescent, as they do not co-express Ki67 (n=0/151) ([Fig. 1g](#F1){ref-type="fig"}; [Supp. Fig. 1g,h](#SD1){ref-type="supplementary-material"}). The CARNs population is non-overlapping with the Lin^−^Sca-1^+^CD133^+^CD44^+^CD117^+^ stem/progenitor population[@R14], since CD117 (c-kit) positive cells in regressed prostate are never luminal (n=0/79) ([Supp. Fig. 1k,l](#SD1){ref-type="supplementary-material"}). Furthermore, since the CARNs population is strictly luminal, it is also distinct from other previously described prostate stem cell populations that are exclusively basal[@R9],[@R10],[@R13].

Bipotentiality and self-renewal {#S2}
===============================

To investigate whether the CARNs population might correspond to prostate epithelial progenitors, we performed *in vivo* lineage-marking using a knock-in allele that places a tamoxifen-inducible Cre recombinase[@R27],[@R28] under the transcriptional control of the *Nkx3.1* promoter ([Supp. Fig. 2a](#SD1){ref-type="supplementary-material"}). We assessed the specificity of the *Nkx3.1^CreERT2^* allele in control crosses with the *R26R-YFP* Cre-reporter[@R29] and the *R26R-lacZ* alleles[@R30], and found that Cre-mediated recombination following tamoxifen administration faithfully recapitulates the endogenous pattern of *Nkx3.1* expression in the intact prostate ([Supp. Fig. 2b--f](#SD1){ref-type="supplementary-material"}).

We performed lineage-marking of CARNs by tamoxifen treatment of castrated *Nkx3.1^CreERT2/+^; R26R-YFP/+* or *Nkx3.1^CreERT2/+^; R26R-lacZ/+* adult males ([Fig. 2a,b](#F2){ref-type="fig"}). As expected for genetic marking of CARNs in regressed prostate, we observed YFP fluorescence/β-galactosidase expression in rare epithelial cells that were strictly luminal ([Supp. Table 1](#SD1){ref-type="supplementary-material"}). These lineage-marked cells were never positive for the basal markers p63 (n=0/98) or CK14 (n=0/131), and almost never positive for CK5 (n=2/93), but always expressed the luminal markers CK18 (n=123/123) and AR (n=94/94) ([Fig. 2 c](#F2){ref-type="fig"}; [Supp. Fig. 3a--d](#SD1){ref-type="supplementary-material"}). Following regeneration, the percentage of lineage-marked cells increased 9-fold (from 0.37% (n=19,825) to 3.3% (n=95,017), *p*\<0.0001) ([Fig. 2d](#F2){ref-type="fig"}), indicating the proliferative potential of CARNs. Although most of the lineage-marked cells in regenerated prostates were luminal, we observed occasional YFP^+^CK5^+^, YFP^+^p63^+^, or β-gal^+^CK14^+^ basal cells, corresponding to 3.0% of lineage-marked cells (n=559) ([Fig. 2e](#F2){ref-type="fig"}; [Supp. Fig. 3g--l](#SD1){ref-type="supplementary-material"}); this percentage of regenerated basal cells is consistent with the low percentage of basal cells lost during regression[@R2]. Since all of the lineage-marked cells were luminal in the regressed prostate, but could give rise to both basal and luminal cells during regeneration, we conclude that the initial CARNs population contains bipotential progenitors.

To investigate the self-renewal of CARNs, we examined whether they could undergo at least one cell division during prostate regeneration to generate a daughter cell that is also a CARN. We determined whether lineage-marked CARNs in castrated *Nkx3.1^CreERT2/+^; R26R-YFP/+* mice would incorporate BrdU during prostate regeneration, while retaining CARN identity (Nkx3.1 expression) after a subsequent prostate regression ([Fig. 2f](#F2){ref-type="fig"}; [Supp. Fig. 3m](#SD1){ref-type="supplementary-material"}). Such triple-positive Nkx3.1^+^YFP^+^BrdU^+^ cells were observed ([Fig. 2g--i](#F2){ref-type="fig"}), providing evidence for CARN self-renewal. In particular, the percentage of BrdU^+^ cells among Nkx3.1^+^YFP^+^ cells, corresponding to CARNs in both the first and second regression, represents the percentage of CARNs undergoing a self-renewal division (24%, n=68; [Supp. Table 2](#SD1){ref-type="supplementary-material"}).

To assess long-term self-renewal, we examined the persistence of lineage-marked cells in *Nkx3.1^CreERT2/+^; R26R-YFP/+* mice after four rounds of regression/regeneration ([Fig. 2j](#F2){ref-type="fig"}). In these mice, YFP^+^ cells represented 3.0% (n=21,559) of the prostate epithelium, similar to the percentage observed after one round ([Fig. 2k,l](#F2){ref-type="fig"}). The persistence of YFP^+^ cells is consistent with the maintenance of a constant stem cell number during regeneration, as suggested by the ability of the epithelium to undergo apparently unlimited serial regeneration[@R5],[@R6], and supports the long-term self-renewal of lineage-marked CARNs.

Single-cell transplantation of CARNs {#S3}
====================================

Next, we investigated whether CARNs could reconstitute prostate tissue in grafts generated from single or multiple lineage-marked CARNs ([Fig 3a](#F3){ref-type="fig"}; [Supp. Fig. 4](#SD1){ref-type="supplementary-material"}). To examine single lineage-marked CARNs, we isolated individual YFP^+^ cells from suspensions of dissociated prostate cells, followed by recombination with rat urogenital mesenchyme cells and renal grafting in immunodeficient male mice ([Supp. Fig. 5a--f](#SD1){ref-type="supplementary-material"}). The resulting grafts generated prostatic ducts with epithelial cells that were entirely YFP^+^ and that expressed luminal markers (E-cadherin, CK18, AR), basal markers (p63, CK5), or neuroendocrine markers (synaptophysin) ([Fig. 3b--g](#F3){ref-type="fig"}; [Supp. Fig. 5g,h](#SD1){ref-type="supplementary-material"}); importantly, these ducts produced secretory proteins and expressed Nkx3.1, which is prostate-specific ([Fig. 3c,i](#F3){ref-type="fig"}). Furthermore, we verified that the tissue formed in these grafts was unequivocally of mouse origin by nuclear morphology[@R31] ([Supp. Fig. 6](#SD1){ref-type="supplementary-material"}). Notably, the frequency of successful single-cell transplantation of lineage-marked YFP^+^ cells (37%, n=43) was significantly greater than for the YFP^−^ control (3%, n=31; p\<0.001) ([Fig. 3j](#F3){ref-type="fig"}).

*Nkx3.1* regulates progenitor maintenance {#S4}
=========================================

Since *Nkx3.1* expression marks the CARNs population, we next investigated whether *Nkx3.1* regulates progenitor maintenance and/or differentiation. First, we examined whether BrdU label-retaining cells (LRCs) might be affected by *Nkx3.1* inactivation, since in many tissues (but not all[@R32]) such long-term growth-quiescent cells are enriched for progenitors[@R33],[@R34]. In the prostate, such LRCs can be identified by BrdU pulse-chase labeling during serial regression/regeneration[@R6] ([Fig. 4a](#F4){ref-type="fig"}). Under conditions in which 1.4% of epithelial cells (n=33,086) retained BrdU-labeling at the fifth regression, 14.0% of CARNs (n=193) were also BrdU-positive ([Fig. 4b--d](#F4){ref-type="fig"}; [Supp. Table 3](#SD1){ref-type="supplementary-material"}), indicating that a significant proportion of CARNs are also LRCs. Secondly, the percentage of LRCs in *Nkx3.1* mutants (0.3%, n=86,601) was significantly less than in wild-type controls (0.8%, n=75,758; *p*=0.003) after five rounds of regression/regeneration ([Fig. 4e--g](#F4){ref-type="fig"}; [Supp. Table 3](#SD1){ref-type="supplementary-material"}), suggesting a decrease in prostate epithelial progenitors.

We also observed phenotypic alterations in *Nkx3.1* mutants after five rounds of serial regeneration, including reduced anterior prostate volume relative to wild-type controls ([Fig. 4h](#F4){ref-type="fig"}). At the histological level, the characteristic hyperplasia and PIN phenotype of *Nkx3.1* homozygous (n=10) as well as heterozygous mice (n=8) was partially suppressed by three or five rounds of serial regeneration, while no abnormalities were observed in wild-type controls (n=9) treated in parallel ([Supp. Fig. 7](#SD1){ref-type="supplementary-material"}, [Supp. Fig 8](#SD1){ref-type="supplementary-material"}; [Supp. Table 4](#SD1){ref-type="supplementary-material"}). Notably, the proliferative index of serially regenerated *Nkx3.1*^−/−^ mutants was similar to controls ([Supp. Fig. 8h,i](#SD1){ref-type="supplementary-material"}), in contrast with the elevated proliferation observed in intact *Nkx3.1* homozygotes[@R21]. Overall, these findings suggest that *Nkx3.1* is required for prostate stem cell maintenance during serial regression/regeneration.

CARNs are a cell of origin for cancer {#S5}
=====================================

Finally, we investigated whether CARNs could represent a target of oncogenic transformation in prostate cancer, by examining the effects of CARNs-specific deletion of the tumor suppressor gene *Pten*, a key regulator of the PI3-kinase/Akt signaling pathway that is frequently inactivated in human prostate cancer. For this purpose, we inducibly deleted *Pten* in the CARNs population of castrated male mice carrying a conditional *Pten* allele[@R35] together with the inducible *Nkx3.1^CreERT2^* allele ([Fig. 5a](#F5){ref-type="fig"}). Following androgen-mediated regeneration of the prostate, we observed rapid formation of high-grade PIN and carcinoma with evidence of microinvasion in the *Nkx3.1^CreERT2/+^; Pten^flox/flox^* mice (n=6), whereas control *Nkx3.1^CreERT2/+^; Pten^+/+^* mice were phenotypically normal (n=6) ([Fig. 5b--e](#F5){ref-type="fig"}). Notably, these PIN and carcinoma lesions showed increased proliferation and loss of basal cells, and displayed membrane-localized phospho-Akt activity ([Fig. 5f--m](#F5){ref-type="fig"}). These data indicate that the CARNs population can serve as a cell of origin for prostate cancer, and that the resulting carcinoma lesions have a luminal phenotype.

Discussion {#S6}
==========

In context with previous studies describing basal stem cells[@R9],[@R10],[@R13], our identification of CARNs as luminal stem cells indicates the existence of distinct non-overlapping stem cell populations in the prostate epithelium. Consequently, we can propose two general models for the lineage relationship between CARNs and a basal stem cell population. One possibility is that basal and luminal cell types may possess independent progenitors that have partially redundant stem cell activities ([Fig. 6a](#F6){ref-type="fig"}). A second possibility is that CARNs represent facultative or "potential" stem cells corresponding to transit-amplifying cells that acquire stem cell properties during regeneration/wound healing responses, as have been described in the mammalian testis and pancreas[@R36]--[@R38] ([Fig. 6b](#F6){ref-type="fig"}). In this model, the facultative stem cells that drive prostate regeneration could be independent from the stem cells for prostate organogenesis, and might co-exist in the adult gland; such a dual progenitor system functions during Drosophila tracheal remodeling[@R39].

In addition, the observed defect in stem cell maintenance in *Nkx3.1* mutants suggests a functional role for *Nkx3.1* expression in CARNs. Thus, *Nkx3.1* inactivation might result in increased differentiation of CARNs and expansion of a proliferative transit-amplifying population ([Supp. Fig. 9](#SD1){ref-type="supplementary-material"}). This interpretation is consistent with the finding that the duration of epithelial proliferation during prostate regeneration is prolonged in *Nkx3.1* mutants relative to wild-type[@R40]. The function of *Nkx3.1* in stem cell maintenance may be direct, consistent with its feedback loop with androgen receptor and role in prostate epithelial differentiation[@R20],[@R41], or may be indirect, for example due to increased oxidative damage with aging[@R42].

Finally, the importance of the stem cell compartment as a target of oncogenic transformation has been highlighted by studies showing that stem cell populations in lung and colon are efficient cells of origin for cancer[@R43],[@R44]. In the case of prostate cancer, the identification of a castration-resistant stem cell population as a cell of origin also has implications for the onset of hormone-refractory disease. Thus, if oncogenic transformation of CARNs can result in the formation of a putative cancer stem cell, the eventual emergence of hormone-refractory disease may be pre-figured through an initiating event during prostate carcinogenesis.

METHODS SUMMARY {#S7}
===============

The *Nkx3.1^CreERT2/+^* allele was generated by gene targeting using standard techniques; the *Nkx3.1* null mutant mice have been previously described[@R21]. *R26R-lacZ* and *Pten* conditional mutant mice were obtained from the Jackson Laboratory Induced Mutant Resource; the *R26R-YFP* mice were provided by Dr. Frank Costantini. All lines were maintained on a hybrid C57BL/6-129/Sv strain background.

Castration of adult male mice was performed using standard techniques. For tamoxifen induction of Cre activity in mice containing *Nkx3.1^CreERT2/+^*, mice were administered 9 mg/40 g tamoxifen for 4 consecutive days. For prostate regeneration, physiological levels of testosterone (1.875 µg/hr) were administered for four weeks by subcutaneous implantation of mini-osmotic pumps (Alzet)[@R45]. When included, BrdU (100 mg/kg) was administered once daily during the first three days of regeneration. For single-cell transplantation, single YFP+ cells were isolated by mouth-pipetting under epifluorescence illumination from a dissociated prostate cell suspension obtained from castrated and tamoxifen-induced *Nkx3.1^CreERT2/+^; R26R-YFP/+* mice. A single YFP^+^ cell (or YFP^−^ cell as a control) was recombined with 2.5 × 10^5^ rat urogenital sinus mesenchyme cells in a 10 µl collagen pad, followed by transplantation under the kidney capsule of *nude* mice and harvesting after 10--12 weeks.

Cryosections were stained with primary antibodies as listed in [Supp. Table 5](#SD1){ref-type="supplementary-material"}, and counterstained with TOPRO3 or DAPI (Invitrogen/Molecular Probes). Secondary antibodies were labeled with Alexa Fluor 488 , 555, or 594 (Invitrogen/Molecular Probes). Immunofluorescence staining was imaged using a Leica TCS5 spectral confocal microscope. Cell counting was performed manually using confocal photomicrographs with at least three animals for each experiment or genotype analyzed.

METHODS {#S8}
=======

Gene targeting and genotyping {#S9}
-----------------------------

The *Nkx3.1^CreERT2/+^* allele was generated by gene targeting using standard techniques[@R46]. The targeting vector was generated using a 5\' arm corresponding to a 3.5 kb PCR fragment from a *Nkx3.1* genomic clone[@R21] up to the translation initiation site of Nkx3.1, and a 3\' arm corresponding to a 4.0 kb PCR fragment of genomic sequence ([Supp. Fig. 2a](#SD1){ref-type="supplementary-material"}). The positive selection cassette corresponded to the self-excising *ACE-Cre/PolII-neo* selection cassette from the pACN vector[@R47], while negative selection was provided by the *PGK-tk* cassette from the *pPNT* vector[@R48]. Primers for generating the 5\' arm were: 5\'-ACC GGA ATT CTC CGC TGC GCG CCG CTT TTG C-3\' and 5\'-ACC CAA GCT TCA TGC CTG CAG GTC GGA GGC C-3\'. Primers to amplify the 3\' arm were: 5\'-CTA GTC TAG AGC GGC TCA CCT CCT TCC TCA-3\' and 5\'-CTA GTC TAG AGG ATG GCA GGA GAG GTC ACT GC-3\'. The gap between the 5\' and 3\' arms is approximately 80 bp, such that the 3\' arm contains the majority of exon 1 together with intron 1, exon 2, and 200 bp of genomic sequence 3\' of the transcription termination site. The pGS-CreER^T2^ vector[@R28] was generously provided by Pierre Chambon, and was modified by insertion of a 65 bp intron from ACE-Cre[@R47] between the *Psh*AI and *Cla*I sites of the CreER^T2^ sequence. Culture and transfection of mouse ES cells followed standard protocols[@R46]. Homologous recombinants in TC1 ES cells[@R49] were selected by positive-negative selection followed by Southern blot screening. 1/260 clones analyzed was properly targeted, and this clone was used to generate germline chimeras.

Mouse genotyping {#S10}
----------------

Genotyping for the *Nkx3.1^CreRT2^* allele was performed by Southern blotting or by PCR using tail genomic DNA. Primers for PCR genotyping were as follows: for the *Nkx3.1* wild-type allele, 5\'-CTC CGC TAC CCT AAG CAT CC-3\' and 5\'-GAC ACT GTC ATA TTA CTT GGA CC-3\', which amplifies a region deleted in the targeting vector; and for the *Nkx3.1^CreERT2^* allele, 5\'-CAG ATG GCG CGG CAA CAC C -3\' and 5\'-GCG CGG TCT GGC AGT AAA AAC -3\'.

The primers for genotyping *Nkx3.1* mutant mice were: 5\'-GCC AAC CTG CCT CAA TCA CTA AGG-3\' (wild-type *Nkx3.1* forward), 5\'-TTC CAC ATA CAC TTC ATT CTC AGT-3\' (mutated forward), and 5\'-GCC AAC CTG CCT CAA TCA CTA AGG-3\' (wild-type and mutated reverse). The primers for genotyping the *R26R-lacZ* Cre-reporter were: 5'-CCG CGC TGT ACT GGA GGC TGA AG -3' (forward) and 5'-ATA CTG CAC CGG GCG GGA AGG AT -3' (reverse). Primers for genotyping the *Pten* conditional (*Pten^flox^*) allele were: 5\'-ACT CAA GGC AGG GAT GAG C-3\' (forward) and 5\'-GTC ATC TTC ACT TAG CCA TTG G-3\' (reverse). Primers for genotyping the *R26R-YFP* mice were: 5\'-GCG AAG AGT TTG TCC TCA ACC-3\' (mutated forward), 5\'-GGA GCG GGA GAA ATG GAT ATG-3\' (wild-type forward) and 5\'-AAA GTC GCT CTG AGT TGT TAT-3\' (wild-type and mutated reverse).

Mouse procedures {#S11}
----------------

Castration of adult male mice was performed using standard techniques[@R50]. Following castration at 8 weeks of age, mice were allowed to regress for four weeks to reach the fully involuted state. For tamoxifen induction of Cre activity in mice containing the *Nkx3.1^CreERT2^* allele, mice were administered 9 mg/40 g tamoxifen (Sigma) suspended in corn oil, or vehicle alone for negative controls, by *i.p.* injection or oral gavage once daily for 4 consecutive days, followed by a chase period of 14 days.

For prostate regeneration, testosterone (Sigma) was dissolved at 25 mg/ml in 100% ethanol and diluted in PEG-400 to a final concentration of 7.5 mg/ml. Testosterone was administered for four weeks at a rate of 1.875 µg per hour delivered by subcutaneous implantation of mini-osmotic pumps (Alzet); this regimen yields physiological levels of serum testosterone[@R45]. When included, BrdU (100 mg/kg) (Sigma) was also administered by *i.p.* injection once daily during the first three days of regeneration to label proliferating cells. After regeneration of the prostate, mice could be euthanized for analysis, or deprived of androgens by pump removal, returning to the regressed state after four additional weeks. At this point, mice were either euthanized for analysis, or osmotic pumps could be reimplanted for additional rounds of serial regression/regeneration.

For tissue recombination and renal grafting, prostate tissues (corresponding to the combined anterior, dorsolateral, and ventral lobes) were dissected and minced to small clumps, followed by enzymatic dissociation with 0.2% collagenase I (Invitrogen) in DMEM media with 10% fetal bovine serum for 90 min. Dissociated tissue was passed sequentially through 21, 23 and 26 gauge needles followed by a 40 µm cell strainer to obtain single-cell suspensions. The resulting cells were assessed for viability by trypan blue exclusion and counted. For grafts containing large numbers of epithelial cells, as in [Supp. Fig. 4](#SD1){ref-type="supplementary-material"}, 2.5 × 10^5^ dissociated prostate cells obtained from castrated and tamoxifen-induced *Nkx3.1^CreERT2/+^; R26R-YFP/+* mice were mixed with 2.5 × 10^5^ dissociated urogenital sinus mesenchyme (UGM) cells from E18.0 rat embryos. UGM cells were obtained from dissected urogenital sinus that was treated for 30 min in 1% trypsin, followed by mechanical dissociation and treatment with 0.1% collagenase B (Roche) for 30 min at 37°, and washing in PBS. Pelleted cell mixtures were resuspended in 10 µl of 1:5 collagen:setting buffer (10x Earle's Balanced Salt Solution (Life Technologies), 0.2 M NaHCO~3~, 50 mM NaOH), and gelatinized in 37°C for 20 minutes. Tissue recombinants were cultured in DMEM media with 10% fetal bovine serum supplemented with 10^−7^ M dihydrotestosterone (DHT) overnight, followed by transplantation under the kidney capsules of *nude* mice. Grafts were harvested after 4--8 weeks of growth for analysis.

For single-cell grafts, as in [Fig. 3](#F3){ref-type="fig"}, a single YFP^+^ (or YFP^−^ cell as a control) was isolated from the dissociated cell suspension from castrated and tamoxifen-induced *Nkx3.1^CreERT2/+^; R26R-YFP/+* prostates by mouth-pipetting under epifluorescence illumination on an Olympus IX51 inverted microscope with DP71 camera. This single cell was then recombined with 2.5 × 10^5^ dissociated urogenital sinus mesenchyme cells obtained from E18.0 rat embryos, and cultured and grafted as above. Grafts were harvested after 10--12 weeks of growth for analysis, and imaged under epifluorescence on an Olympus SZX16 stereomicroscope with DP71 camera. The resulting graft tissue was analyzed for YFP and other marker expression as described below, and counterstained with DAPI for visualization of nuclear morphology at high-power to distinguish mouse from rat nuclei[@R31].

Grafts recovered from transplantation of a single lineage-marked YFP^+^ cell (n=16/43, 37%) were confirmed to be of mouse origin by YFP expression and nuclear morphology ([Supp. Fig. 6](#SD1){ref-type="supplementary-material"}), while the single graft (n=1/31, 3%) arising from a YFP^−^ cell was confirmed to be of mouse origin by nuclear morphology. Generation of prostatic ducts by a YFP^−^ cell might result from a CARN that was not lineage-marked by tamoxifen-induction, which is inefficient, or alternatively from a distinct stem cell type in the prostate epithelium. We note that a significant percentage (n=13/74, 18%) of the grafts contained ducts of rat origin, which are not included in [Fig. 3j](#F3){ref-type="fig"}. These rat ducts likely arise from rat urogenital epithelial cells that are difficult to completely dissociate from the urogenital mesenchyme used in the graft, and can populate the graft under conditions in which the epithelial contribution is limiting.

For histological and immunofluorescence analysis, individual prostate lobes or renal grafts were dissected, and then fixed in 4% paraformaldehyde for subsequent cryoembedding in OCT compound (Sakura), or fixed in 10% formalin followed by paraffin embedding. Volume of dissected anterior prostate lobes was determined by physical displacement of known volumes of PBS solution in 0.5 ml centrifuge tubes.

Histology and immunostaining {#S12}
----------------------------

Hematoxylin-eosin staining was performed using standard protocols on 6 µm paraffin sections. β-galactosidase staining was performed using 12 micron cryosections, which were incubated in staining solution (0.1 M PBS, 1.3 mM MgCl~2~, 1 mg/ml X-gal , 0.02% Nonidet P--40, 5 mM K~4~Fe(CN)~6~, 5 mM K~3~Fe(CN)~6~, and 0.01% Na-deoxycholate) for 3 hours or overnight, followed by fixation in 10% formalin for 2 to 5 hours. Direct visualization of YFP was performed after washing 10 µm cryosections in PBST (PBS with 0.1% Triton X-100) 3 times, incubation with TOPRO3 (1:1000 diluted in PBST) (Invitrogen/Molecular Probes) for 30 min, and mounting with VECTASHIELD mounting medium (Vector Labs), which contains DAPI.

For immunohistochemical staining, 6 µm paraffin sections were deparaffinized in xylene, followed by antigen retrieval through boiling in antigen unmasking solution (Vector Labs). Slides were blocked in 10% normal serum or with blocking reagents provided in the M.O.M. kit (Vector Labs) for mouse primary antibodies, then incubated with primary antibodies overnight at 4 °C or room temperature. Primary antibodies and dilutions utilized are listed in [Supp. Table 5](#SD1){ref-type="supplementary-material"}. Secondary antibodies were obtained from Vectastain ABC kits (Vector Labs) and diluted 1:250 or 1:500. The signal was enhanced using the Vectastain ABC system and visualized with the NovaRed Substrate Kit (Vector Labs). The slides were counterstained with Harris Modified Hematoxylin (1:4 diluted in H~2~O) (Fisher Scientific) and mounted with Clearmount (American Master\*Tech Scientific). Immunohistochemical staining was imaged using a Nikon Eclipse E800 microscope equipped with a Nikon DXM1200 digital camera.

Immunofluorescence staining was performed on either 6 micron paraffin sections or 10 micron cryosections, which were incubated in 3% H~2~O~2~ and Antigen Unmasking Solution (Vector Labs). Primary antibodies and dilutions utilized are listed in [Supp. Table 5](#SD1){ref-type="supplementary-material"}. Slides were incubated with 10% normal goat (Vector Labs) or donkey serum (Sigma) and with primary antibodies diluted in the 10% normal goat or donkey serum overnight at 4°C or room temperature. Slides then were incubated with secondary antibodies (diluted 1:500 in PBST) labeled with Alexa Fluor 488, 555, or 594 (Invitrogen/Molecular Probes). Detection of Nkx3.1, GFP, and Cre was enhanced using tyramide amplification (Invitrogen/Molecular Probes) by incubation of slides with HRP-conjugated secondary antibody (1:100 dilution) (Invitrogen/Molecular Probes), followed by incubation with tyramide 488 or 555 for 6 min. Sections were counterstained with TOPRO3 or TOTO3 (diluted 1:1000 in PBST) (Invitrogen/Molecular Probes) to visualize nuclei, and mounted with VECTASHIELD mounting medium (Vector Labs), which contains DAPI. Immunofluorescence staining was imaged using a Leica TCS5 spectral confocal microscope.

Quantitation and statistics {#S13}
---------------------------

To calculate the number of CARNs in the regressed mouse prostate, we determined that there are an average of 112,000 total cells (n=5 animals; all lobes combined), of which 59% are epithelial as determined by immunoreactivity for the pan-epithelial marker CD24 (ref. [@R9]). Since 0.7% of epithelial cells in the regressed prostate are CARNs, there are approximately 460 CARNs in the total prostate. To determine the number of lineage-marked cells in the regressed prostate, we visualized 320 live YFP^+^ cells in dissociated prostate tissue (all lobes combined) from 5 castrated lineage-marked *Nkx3.1^CreERT2/+^; R26R-YFP/+* mice, for a total of 64 YFP^+^ live cells/mouse. For the experiment in [Supp. Fig. 4](#SD1){ref-type="supplementary-material"}, we performed 2 recombinations from these dissociated prostate cells, so that there were approximately 160 live YFP^+^ cells used in each graft.

For immunostaining experiments, cell numbers were counted manually using confocal 40x and 63x photomicrographs. Statistical analyses were performed using a two-sample T-test, *X*^2^ test, or Fisher's Exact test as appropriate. At least three animals for each experiment or genotype were analyzed.
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![Expression of *Nkx3.1* in epithelial cells of the intact and regressed anterior prostate\
**a**, Schematic prostate duct in the intact, regressed, and regenerated states. Most luminal cells undergo apoptosis during regression, whereas most basal cells survive; hence, the process of regeneration primarily produces luminal cells. **b**, Nkx3.1 expression in all luminal cells of the wild-type intact prostate. **c**, Nkx3.1 expression is mostly absent in regressed prostate, except for rare castration-resistant Nkx3.1-expressing cells (CARNs, arrows. **d**, Expression of Nkx3.1 in regenerated prostate, showing similarity to **b**. **e**, Immunostaining for Nkx3.1 and β-catenin shows clustering of CARNs. **f, g**, CARNs are strictly luminal, as shown by lack of co-staining for Nkx3.1 (arrows) and p63 (**f**), and by co-localization of Nkx3.1 (arrows) with cytokeratin 18 (CK18) (**g**). Scale bars correspond to 25 microns.](nihms137158f1){#F1}

![Bipotentiality and self-renewal of CARNs *in vivo*\
**a**, Strategy for lineage-marking experiment. **b**, Timeline for the experiment. **c**, YFP does not co-localize with p63 in lineage-marked cells of a castrated and tamoxifen-induced *Nkx3.1^CreERT2/+^; R26R-YFP/+* anterior prostate. **d**, Clusters of YFP^+^ cells in a lineage-marked and regenerated prostate. **e**, Co-localization of YFP and cytokeratin 5 (CK5) in lineage-marked basal cells (arrows) of a regenerated prostate. **f**, Time-line for self-renewal experiment. **g--i**, Co-localization of Nkx3.1, YFP, and BrdU immunostaining (arrow) in anterior prostate, shown as an overlay (**g**) and individual channels (**h, i**); YFP^+^BrdU^+^ neighbors are indicated (arrowheads). **j**, Strategy for four-round serial regression/regeneration assay of long-term CARNs self-renewal. **k, l**, Clusters of YFP^+^ cells in the lineage-marked prostate after four rounds of serial regression/regeneration. Scale bars correspond to 25 microns.](nihms137158f2){#F2}

![Generation of prostatic ducts in renal grafts by single lineage-marked CARNs\
**a**, Strategy for tissue recombinant/renal graft analyses using a single YFP^+^ cell (or single YFP^−^ cell as a control). **b, c**, Hematoxylin-eosin (H&E) staining of prostatic ducts in a graft derived from a single YFP^+^ cell; note presence of basal cells (arrows) and secretions (**c**). **d**, All epithelial cells in single-YFP+ derived duct express YFP, including p63^+^ basal cells (arrows). **e--g**, Expression of luminal marker CK18 (**e**), basal marker p63 (**f**), and neuroendocrine marker synaptophysin (Syn) (**g**) in ducts from single YFP^+^ cells. **h, i**, Expression of androgen receptor (AR) (**h**) and Nkx3.1 (**i**) confirm prostate identity of ducts. **j**, Summary of single-cell transplantation data. Scale bars in **d--f, h, i** correspond to 25 microns, in **b, c, g** to 50 microns.](nihms137158f3){#F3}

![*Nkx3.1* mutants display prostate epithelial defects in a serial regeneration assay\
**a**, Time-line for analysis of label-retaining cells (LRCs). **b--d**, Overlap of CARNs with LRCs in a serially regressed prostate, shown as an overlay (**b**) and individual panels (**c, d**). Arrow in **b--d** indicates a Nkx3.1^+^BrdU^+^ cell; arrowhead in c indicates a CARN that is BrdU^−^. **e**, Time-line for serial regression/regeneration analyses. **f, g**, Decreased number of LRCs (arrows) in *Nkx3.1^−/−^* anterior prostate (**g**) relative to wild-type controls (**f**) after serial regeneration. **h**, Decreased volume of *Nkx3.1^−/−^* anterior prostate relative to wild-type and *Nkx3.1^+/−^* prostates following serial regeneration, and to intact wild-type and *Nkx3.1^−/−^* prostates. Error bars correspond to one standard deviation. Scale bars correspond to 25 microns.](nihms137158f4){#F4}

![The CARNs population contains a cell type of origin for prostate cancer\
**a**, Time-line for inducible conditional deletion of *Pten* in CARNs. **b--e**, Hematoxylin-eosin (H&E) staining of anterior prostate from control *Nkx3.1^CreERT2/+^; Pten^+/+^* (**b, d**) and *Nkx3.1^CreERT2/+^; Pten^flox/flox^* mice (**c, e**), shown at low-power (**b, c**) and high-power (**d, e**). The *Nkx3.1^CreERT2/+^; Pten^flox/flox^* prostate contains high-grade PIN/carcinoma lesions with local invasive epithelium (arrows, **e**). **f, g**, Detection of p63^+^ basal cells shows loss of basal cells except at the periphery (arrows, **g**) of PIN/carcinoma lesions. **h, i**, Elevated Ki67 immunostaining in PIN/carcinoma lesions. **j, k**, Phospho-Akt immunostaining with cell membrane localization (arrows, **k**) in PIN/carcinoma lesions. **l, m**, Pten immunostaining is ubiquitous in control *Nkx3.1^CreERT2/+^; Pten^+/+^* prostate epithelium, but is restricted to basal cells and scattered luminal cells in induced *Nkx3.1^CreERT2/+^; Pten^flox/flox^* prostate. Scale bars correspond to 100 microns.](nihms137158f5){#F5}

![Possible lineage relationships in the prostate epithelium\
**a**, Independent stem cells for basal and luminal epithelium may give rise to differentiated cell types through multipotent progenitors (MPP) and transit-amplifying progenitors, with some bipotentiality (dashed arrows). In this model, CARNs would correspond to the luminal stem cells. **b**, Alternatively, stem cells for prostate organogenesis may be basal, but luminal transit-amplifying cells, including CARNs, can acquire stem cell properties during regeneration (red arrows), thus acting as facultative or "potential" stem cells.](nihms137158f6){#F6}
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